Ensysce Biosciences (ENSC) investor relations material

Executive summary

• Achieved major clinical and regulatory milestones in 2025, including initiation of Phase 3 trial for PF614 and progress on PF614-MPAR under Breakthrough Therapy designation.

• Advanced commercial manufacturing readiness for PF614 and expanded intellectual property protection through new patents in the US and Europe.

• Pipeline growth included development of PF9001 for opioid use disorder and exploration of TAAP and MPAR technologies for ADHD and other indications.

Financial highlights

• Cash and cash equivalents were $4.3 million as of December 31, 2025, up from $3.5 million at year-end 2024.

• Federal grant funding totaled $5.1 million for 2025, nearly flat year-over-year.

• Research & development expenses rose to $10.4 million in 2025 from $7.2 million in 2024, driven by increased clinical activity.

• General & administrative expenses were $4.9 million in 2025, up slightly from $4.7 million in 2024.

• Net loss attributable to common stockholders was $10.2 million for 2025, compared to $8.0 million in 2024.

Outlook and guidance

• PF614-301 Phase 3 enrollment progressing rapidly, with regulatory engagement supporting manufacturing and commercialization pathway.

• PF614-MPAR development accelerated under Breakthrough Therapy designation, with FDA support for overdose-protection labeling and streamlined regulatory pathway.

• Continued focus on expanding pipeline and leveraging technology platforms for new indications.